In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Argos Therapeutics Inc. (NASDAQ:ARGS) reported that Pharmstandard International S.a. has picked up 18,362,883 of common stock as of 2017-06-26.
The acquisition brings the aggregate amount owned by Pharmstandard International S.a. to a total of 18,362,883 representing a 39.9% stake in the company.
For those not familiar with the company, Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.
A glance at Argos Therapeutics Inc. (NASDAQ:ARGS) key stats reveals a current market capitalization of $15.08 Million based on $41.35 Million shares outstanding and a price at last close of $0.390 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-10-07, Pharmstandard picked up 21,000 at a purchase price of $4.73. This brings their total holding to 13,242,279 as of the date of the filing.
On the sell side, the most recent transaction saw Braun unload 2,000 shares at a sale price of $5.03. This brings their total holding to 1,994,580.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an Argos Therapeutics Inc. (NASDAQ:ARGS) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.